Contributing Member of the Healthcare Councils

Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.

GLG News by this Author

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

benefit of Iressa

April 27, 2009

Analysis of:IRESSA (Gefitinib) Recommended for Approval for the Treatment of Non-Small Cell Lung Cancer in Europe | www.pipelinereview.com

I have a patient with non small cell carcinoma of the lung who has had a great response for over seven years on this medication. She was a perfect fit- female, non smoker. After seven years she is NED. She was close to being referred to hospice seven years ago. She is receiving the med at present free of charge from the company. I hope that ultimately this agent will again be available in the US. Stephen Schreibman, MD

Erbitux in K ras wild metastatic first line treatment

January 6, 2009

Analysis of:Merck Serono: Study Published In JCO Shows Erbitux Enhances Efficacy In MCRC Patients With KRAS Wild-Type Tumors In 1st-Line Setting | www.medicalnewstoday.com

As a medical oncologist, I would want to know how folfox/erbitux in k ras wild patients fared against the standard of folfox/avastin for metastatic first line patients. Stephen Schreibman, MD

Page : 11 to 2 of 2

Subscribe to Updates

By RSS